Home › Funds › BRAIDWELL LP › XENE

BRAIDWELL LP position in XENE

XENON PHARMACEUTICALS INC · Health Care

BRAIDWELL LP reported holding 1,131,452 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$68.3M, representing 2.69% of its reported portfolio and ranking #8 among its reported holdings. BRAIDWELL LP has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.13M sh
Reported value held$68.29M
Portfolio Weight2.69%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BRAIDWELL LP's XENE position evolved

BRAIDWELL LP first disclosed a stake in XENE in Q3 2023 at 2,103,396 shares (US$71.9M). The position peaked in Q3 2025 at 3,605,029 shares, worth US$144.7M. Across 12 filings, BRAIDWELL LP increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,131,452 shares valued at US$68.3M — a reduction of -207,000 shares quarter over quarter.. Notable position changes include a 96% increase in Q2 2024 (shares were roughly flat over the following quarter), a 33% increase in Q2 2025 (shares rose 28% over the following quarter), a 49% trim in Q4 2025 (shares rose 30% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.10M $71.85M New
Q4 2023 1.65M $75.88M Reduce
Q1 2024 1.31M $56.31M Reduce
Q2 2024 2.56M $99.84M Add
Q3 2024 2.71M $106.58M Add
Q4 2024 2.91M $114.23M Add
Q1 2025 2.71M $90.92M Reduce
Q2 2025 3.61M $112.84M Add
Q3 2025 3.61M $144.74M Hold
Q4 2025 1.83M $81.80M Reduce
Q1 2026 1.34M $77.83M Reduce
Q2 2026 1.13M $68.29M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has BRAIDWELL LP held XENE?

BRAIDWELL LP has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BRAIDWELL LP's current position in XENE?

As of Q2 2026, BRAIDWELL LP holds 1.13M shares of XENE (XENON PHARMACEUTICALS INC), valued at $68.29M, representing 2.69% of its reported portfolio and ranking #8.

Has BRAIDWELL LP been buying or selling XENE?

In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in XENE. The position peaked in Q3 2025 at 3.61M shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.